Amedica announced that it has entered into a distribution agreement with K2M that will provide surgeons and hospitals in Europe with access to Amedica’s silicon nitride interbody spinal fusion devices.

Earlier this year and according to a company release, Amedica and K2M conducted a successful pilot programme in select markets in Europe where surgeons were provided the opportunity to integrate silicon nitride interbody devices into their offerings for patients suffering from a variety of disorders requiring spinal fusion. This pilot programme demonstrated a need in these strategic markets for spinal fusion devices devised from a different biomaterial.

“K2M is committed to providing the best and most innovative technologies to meet the needs of patients around the world suffering from spinal disorders and we believe our relationship with Amedica will help us further this goal,” said Eric Major, K2M’s president and chief executive officer. “We are thrilled to make Amedica’s silicon nitride interbody spinal fusion devices part of our comprehensive international product portfolio.”

“K2M has an outstanding sales and marketing team that has created a global reputation for providing leading edge technology to their customers. Our silicon nitride interbody product line will be integrated into K2M’s current portfolio of interbody spinal fusion devices,” said Eric K Olson, president and chief executive officer, Amedica. “We believe it is evident that there is a need in Europe for interbody fusion devices that exceed the capabilities of existing PEEK and titanium-based devices. With this distribution channel in place, we believe silicon nitride interbody spinal fusion devices will increasingly be the solution that surgeons rely on to deliver optimal patient outcomes in spinal fusion procedures.”